Back to Browse Journals » Journal of Receptor, Ligand and Channel Research » Volume 4

Specific mechanism of action of amisulpride in the treatment of schizophrenia and correlation with clinical response and tolerability

Authors Juruena MF, de Sena EP, de Oliveira IR

Published 26 August 2011 Volume 2011:4 Pages 49—55

DOI https://doi.org/10.2147/JRLCR.S6239

Review by Single-blind

Peer reviewer comments 3

Mario F Juruena1, Eduardo Pondé de Sena2, Irismar Reis de Oliveira3
1Stress and Affective Disorders Programme, Department of Neuroscience and Behaviour, Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Sao Paulo, Brazil; 2Department of Pharmacology, Institute of Health Sciences, Federal University of Bahia, Salvador, Brazil; 3Department of Neurosciences and Mental Health, School of Medicine, Federal University of Bahia, Salvador, BA, Brazil

Abstract: The treatment of schizophrenia has advanced because the therapeutic efficacy, tolerability, and safety profiles of atypical antipsychotics seem to be superior to those of classical neuroleptics. Amisulpride is an atypical antipsychotic drug with a unique receptor pharmacology, which is dose-dependent. As could be predicted from the pharmacologic profile of a pure D2/D3 receptor blocker, amisulpride is an atypical antipsychotic agent, effective for positive and negative symptoms, which can bring about additional improvement in the social functioning and quality of life of patients with schizophrenia. Amisulpride has one of the lowest potentials for weight gain of all the antipsychotic agents, and is clearly associated with lower use of anti-parkinsonian medication and with fewer dropouts due to adverse events than conventional antipsychotics. Amisulpride is well tolerated in terms of anxiety and insomnia. Amisulpride has a pronounced prolactin-elevating effect which appears to be independent of dosage and duration of administration. Hyperprolactinemia rapidly reverses after amisulpride discontinuation. Amisulpride benefits patients with negative symptoms, and is the only antipsychotic to demonstrate efficacy in patients with predominantly negative symptoms. Amisulpride maintains its efficacy when used for medium-/long-term treatment, as demonstrated in studies of up to 12 months. Amisulpride has the best evidence as an effective adjunct to clozapine treatment. In conclusion, amisulpride is an antipsychotic agent with proven efficacy and good tolerability.

Keywords: antipsychotic agents, amisulpride, adverse events, pharmacology

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other article by this author:

Safety and tolerability of antipsychotics: focus on amisulpride

Mario F Juruena, Eduardo Pondé de Sena, Irismar Reis de Oliveira

Drug, Healthcare and Patient Safety 2010, 2:205-211

Published Date: 1 October 2010

Readers of this article also read:

Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis

Cutolo M, Meroni M

Journal of Inflammation Research 2013, 6:129-137

Published Date: 15 November 2013

Effects of Arthro-7® in relieving symptoms of osteoarthritis with mild to moderate arthralgia [Corrigendum]

Xie Q, Zhou T, Yen L, Shariff M, Nguyen T, Kami K, Gu P, Liang L, Rao J, Shi R

Nutrition and Dietary Supplements 2013, 5:7-8

Published Date: 16 May 2013

Alteration patterns of trabecular bone microarchitectural characteristics induced by osteoarthritis over time

Lee JH, Chun KJ, Kim HS, Kim SH, Han P, Jun Y, Lim D

Clinical Interventions in Aging 2012, 7:303-312

Published Date: 10 August 2012

Genetics of rheumatoid arthritis: GWAS and beyond

McAllister KM, Eyre S, Orozco G

Open Access Rheumatology: Research and Reviews 2011, 3:31-46

Published Date: 3 June 2011

Nonsteroidal anti-inflammatory drug gastropathy: new avenues for safety

Roth SH

Clinical Interventions in Aging 2011, 6:125-131

Published Date: 30 May 2011

Erratum

Schuelert N, Russell FA, McDougall JJ

Orthopedic Research and Reviews 2011, 3:9-10

Published Date: 1 March 2011